

## **Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024**

**DENVER, CO / May 8, 2024** / Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024. The Company has scheduled a conference call and webcast that same day, Wednesday, May 15, 2024, at 4:30 p.m. Eastern time, to review the results followed by a question and answer session.

### **Conference Call Details**

**Date and Time:** Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time

**Call-in Information:** Interested parties can access the conference call by dialing (888) 506-0062 for U.S. callers or +1 (973) 528-0011 for international callers and using the participant access code 300411.

**Webcast Information:** The webcast will be accessible live and archived at <https://www.webcaster4.com/Webcast/Page/2142/50379>, and accessible on the Investors section of the Company’s website at <https://investors.aytubio.com/> under Events & Presentations.

**Replay:** A teleconference replay of the call will be available until May 29, 2024 at (877) 481-4010 for U.S. callers or +1 (919) 882-2331 for international callers and using replay access code 50379.

### **About Aytu BioPharma, Inc.**

Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotelpla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit [aytubio.com](http://aytubio.com).

### **Contacts for Investors:**

Mark Oki, Chief Financial Officer

Aytu BioPharma, Inc.  
moki@aytubio.com

Robert Blum or Roger Weiss  
Lytham Partners  
aytu@lythampartners.com

**SOURCE:** Aytu BioPharma, Inc.



View the original press release on [accesswire.com](https://www.accesswire.com)